Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
114M
-
Number of holders
-
157
-
Total 13F shares, excl. options
-
115M
-
Shares change
-
-7.8M
-
Total reported value, excl. options
-
$401M
-
Value change
-
-$26.3M
-
Put/Call ratio
-
0.17
-
Number of buys
-
55
-
Number of sells
-
-94
-
Price
-
$3.50
Significant Holders of FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) as of Q3 2024
197 filings reported holding FATE - FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share as of Q3 2024.
FATE THERAPEUTICS INC - Common Stock, par value $0.001 per share (FATE) has 157 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 115M shares
.
Largest 10 shareholders include Redmile Group, LLC (13.2M shares), BlackRock, Inc. (10.5M shares), VANGUARD GROUP INC (10.4M shares), Deep Track Capital, LP (5.57M shares), STATE STREET CORP (5.25M shares), Boxer Capital, LLC (4.96M shares), Bellevue Group AG (4.84M shares), CITADEL ADVISORS LLC (4.28M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (3.56M shares), and JOHNSON & JOHNSON (3.38M shares).
This table shows the top 157 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.